David Chatenet

David Chatenet


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2012 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
David ChatenetDavid Chatenet
David Chatenet
MLM Létourneau
M Létourneau
QNQt Nguyen
Qt Nguyen
NDNd Doan
Nd Doan
JDJ Dupuis
J Dupuis
AFA Fournier
A Fournier
Background and Purpose: Recent evidence suggested that urotensin II (UII) and its paralog peptide UII‐related peptide (URP) might exert common but also divergent physiological actions. Unfortunately, none of the existing antagonists were designed to discriminate specific UII‐ or URP‐associated actions, and our understanding, on how these two endogenous peptides can trigger different, but also common responses, is limited.Experimental Approach: Ex vivo rat and monkey aortic ring contraction as well as dissociation kinetics studies using transfected CHO cells expressing the human urotensin (UT) receptors were used in this study.Key Results: Ex vivo rat and monkey aortic ring contraction studies revealed the propensity of [Pep4]URP to decrease the maximal response of human UII (hUII) without any significant change in potency, whereas no effect was noticeable on the URP‐induced vasoconstriction. Dissociation experiments demonstrated the ability of [Pep4]URP to increase the dissociation rate of hUII, but not URP. Surprisingly, URP, an equipotent UII paralog, was also able to accelerate the dissociation rate of membrane‐bound 125I‐hUII, whereas hUII had no noticeable effect on URP dissociation kinetics. Further experiments suggested that an interaction between the glutamic residue at position 1 of hUII and the UT receptor seems to be critical to induce conformational changes associated with agonistic activation. Finally, we demonstrated that the N‐terminal domain of the rat UII isoform was able to act as a specific antagonist of the URP‐associated actions.Conclusion: Such compounds, that is [Pep4]URP and rUII(1–7), should prove to be useful as new pharmacological tools to decipher the specific role of UII and URP in vitro but also in vivo.

7 January 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Francesco MerlinoFrancesco Merlino
Francesco Merlino
ÉBÉtienne Billard
Étienne Billard
AYAli Munaim Yousif
Ali Munaim Yousif
SMSalvatore Di Maro
Salvatore Di Maro
DBDiego Brancaccio
Diego Brancaccio
PGPaolo Grieco
Paolo Grieco

16 July 2012 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
TNThi Tuyet Nhung Nguyen
Thi Tuyet Nhung Nguyen
BFBenjamin Folch
Benjamin Folch
MLMyriam Létourneau
Myriam Létourneau
David VaudryDavid Vaudry
David Vaudry
NTNam Hai Truong
Nam Hai Truong
AFAlain Fournier
Alain Fournier


1 January 2013 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
David ChatenetDavid Chatenet
David Chatenet
TNThi-Tuyet M. Nguyen
Thi-Tuyet M. Nguyen
MLMyriam Létourneau
Myriam Létourneau
AFAlain Fournier
Alain Fournier
MLMyriam L
Myriam L
The urotensinergic system plays central roles in the physiological regulation of major mammalian organ systems, including the cardiovascular system. As a matter of fact, this system has been linked to numerous pathophysiological states including atherosclerosis, heart failure, hypertension, diabetes as well as psychological, and neurological disorders. The delineation of the (patho)physiological roles of the urotensinergic system has been hampered by the absence of potent and selective antagonists for the urotensin II-receptor (UT). Thus, a more precise definition of the molecular functioning of the urotensinergic system, in normal conditions as well as in a pathological state is still critically needed. The recent discovery of nuclear UT within cardiomyocytes has highlighted the cellular complexity of this system and suggested that UT-associated biological responses are not only initiated at the cell surface but may result from the integration of extracellular and intracellular signaling pathways. Thus, such nuclear-localized receptors, regulating distinct signaling pathways, may represent new therapeutic targets. With the recent observation that urotensin II (UII) and urotensin II-related peptide (URP) exert different biological effects and the postulate that they could also have distinct pathophysiological roles in hypertension, it appears crucial to reassess the recognition process involving UII and URP with UT, and to push forward the development of new analogs of the UT system aimed at discriminating UII- and URP-mediated biological activities. The recent development of such compounds, i.e. urocontrin A and rUII(1–7), is certainly useful to decipher the specific roles of UII and URP in vitro and in vivo. Altogether, these studies, which provide important information regarding the pharmacology of the urotensinergic system and the conformational requirements for binding and activation, will ultimately lead to the development of potent and selective drugs.

5 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ADAntoine Douchez
Antoine Douchez
EBEtienne Billard
Etienne Billard
THTerence E. Hébert
Terence E. Hébert
David ChatenetDavid Chatenet
David Chatenet
William D. LubellWilliam D. Lubell
William D. Lubell